Inaugurated in June 2010 as a new facility - thanks to the support received from the Welfare Projects Division of the ”la Caixa” Foundation, the Research Unit for Molecular Therapy of Cancer (UITM) - ”la Caixa” is dedicated to complex clinical trials with drugs in early development (Phase I and early Phase II trials) focusing on novel targets.
Research carried out by VHIO´s Early Clinical Drug Development Group at our Unit focuses both on the development of new drugs based on the molecular profile of each tumor as well as the optimization of treatment regimes using combinations of new drugs with those already existing.
In line with VHIO´s translational model, our research is also linked with the different research areas carried out by other VHIO groups. We connect molecular biology and the best tumor models with pharmacology and innovative clinical research. VHIO scientists also collaborate closely in the trials to facilitate biomarker development, a profound understanding of the mechanism of action, as well as research in mechanisms of resistance.
In partnership with the Molecular Pathology and the Cancer Genomics Groups we perform molecular analysis of the patients´ tumors in order to select the best possible treatment with the experimental therapeutics available - one step closer to realizing the true promise of personalized medicine.
Our UITM team is highly multidisciplinary incorporating medical oncologists, clinical trial coordinators and data managers, nurses and nurse technicians, pharmacists, as well as administrative personnel. Excellent patient treatment and care as well as pioneering research is also made possible thanks to the tight connectivity and collaboration with many other oncology professionals including pathologists from the Vall d’Hebron University Hospital’s Molecular Pathology Department, radiologists and interventional radiologists, as well as the Clinical Trials Office, Database Management, and healthcare specialists (dermatologists, cardiologists, ophthalmologists).